Published in Drug Des Devel Ther on November 18, 2010
Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation. Int J Womens Health (2012) 0.76
Bisphosphonate-induced Severe Hypocalcemia - A Case Report -. J Bone Metab (2012) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res (2007) 14.84
Epidemiology and outcomes of osteoporotic fractures. Lancet (2002) 13.09
Osteoporosis prevention, diagnosis, and therapy. JAMA (2001) 12.60
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab (2004) 8.36
Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med (2006) 7.46
Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med (2007) 7.38
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg (2005) 7.36
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone (1995) 5.76
American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg (2007) 5.38
Esophagitis associated with the use of alendronate. N Engl J Med (1996) 4.89
Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg (2007) 4.26
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br (2007) 4.10
Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma (2008) 3.74
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury (2008) 3.50
Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc (2006) 3.41
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A (2006) 2.73
Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med (2008) 2.66
Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg (2007) 2.53
Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med (2000) 2.46
Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc (2008) 2.36
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int (2008) 2.29
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol (2008) 2.28
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med (2009) 2.27
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med (1991) 2.00
Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab (2008) 1.99
Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med (2005) 1.99
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone (2007) 1.97
Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res (2007) 1.94
Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract (2006) 1.84
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer (2009) 1.78
Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica (2006) 1.71
Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med (2006) 1.59
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med (2009) 1.56
Bisphosphonate nephrotoxicity. Kidney Int (2008) 1.53
Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc (2009) 1.39
Bisphosphonate-associated adverse events. Hormones (Athens) (2009) 1.36
Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol (2008) 1.36
Musculoskeletal pain in female asylum seekers and hypovitaminosis D3. BMJ (2004) 1.30
The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer (2007) 1.27
Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract (2007) 1.27
Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med (2009) 1.18
Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res (2009) 1.17
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc (2010) 1.16
Treatments for osteoporosis - looking beyond the HORIZON. N Engl J Med (2007) 1.10
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast (2010) 1.03
Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res (2009) 1.03
Bisphosphonates and time to osteonecrosis development. Oncologist (2009) 1.03
Safety of bisphosphonates in the treatment of osteoporosis. Am J Med (2009) 1.02
Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res (2010) 1.02
Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club. Osteoporos Int (2007) 0.99
Severe oral ulcerations induced by alendronate. Clin Rheumatol (1999) 0.99
Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol (2009) 0.99
Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag (2008) 0.97
A case report: zoledronic acid-induced anterior uveitis. Med Oncol (2007) 0.94
A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS (2009) 0.94
Long-term effects of strokes on bone mass. Am J Phys Med Rehabil (1995) 0.92
Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol (2009) 0.92
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int (2007) 0.91
Changes in bone mineral content and density after stroke. Am J Phys Med Rehabil (1993) 0.91
Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol (2006) 0.90
Alendronate-induced synovitis. J Rheumatol (2008) 0.90
Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss. Clin Cancer Res (2008) 0.89
Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Expert Rev Anticancer Ther (2009) 0.89
Acute polyarthritis related to once-weekly alendronate in a woman with osteoporosis. J Rheumatol (2004) 0.88
Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer. BMC Cancer (2005) 0.88
Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging (2009) 0.86
Unilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer. J Rheumatol (2008) 0.85
Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2008) 0.85
A single infusion of zoledronate prevents bone loss after stroke. Stroke (2007) 0.84
Bisphosphonate-associated scleritis: a case report and review. South Med J (2005) 0.84
Zoledronic acid: a review of its use in the treatment of osteoporosis. Drugs Aging (2008) 0.82
Management of osteoporosis in the aging male: focus on zoledronic acid. Clin Interv Aging (2009) 0.82
Scleritis complicating zoledronic acid infusion. Clin Lymphoma Myeloma (2006) 0.81
Chronic erosive and ulcerative oral lesions caused by incorrect administration of alendronate. J Am Acad Dermatol (2004) 0.80
Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis. Joint Bone Spine (2010) 0.80
Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol (2006) 0.79
Flare-up of hand osteoarthritis caused by zoledronic acid infusion. Osteoporos Int (2009) 0.78
Zoledronic acid for cancer therapy--induced and postmenopausal bone loss. Expert Opin Pharmacother (2008) 0.77
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women. Clin Interv Aging (2008) 0.77
A clinician's perspective on the use of zoledronic acid in the treatment of postmenopausal osteoporosis. J Clin Densitom (2008) 0.77
Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol (2003) 0.76
Treatment of postmenopausal osteoporosis, patient perspectives - focus on once yearly zoledronic acid. Patient Prefer Adherence (2009) 0.76
Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application. Medscape J Med (2009) 0.76
Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis. Osteoporos Int (2009) 0.76
Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis. Med Lett Drugs Ther (2009) 0.75
Management of the side-effects of intravenous bisphosphonates: targeting the serum parathyroid hormone elevation. Ann Oncol (2006) 0.75